Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Global E Online Ltd (GLBE) Price & Performance

Abeona Therapeutics Inc
Global E Online Ltd

Price performance

Price movement over the last 24 hours

Key statistics

Abeona Therapeutics Inc vs Global E Online Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Global E Online Ltd trades at $36 (market cap $6.21B). The key difference: Global E Online Ltd is far larger — about 16.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Global E Online Ltd nearer its low. Which is the better fit depends on your goals.

ABEOGLBE
Market Cap
$373.32M$6.21B
Sector
HealthTechnology
52-Week High
$7.23$41.59
52-Week Low
$4.17$27.54
Enterprise Value
$228.22M$5.68B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

Global E Online Ltd

GLBE trades at $37.31, up 1.25% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 33% revenue growth in Q1 2026 and expanding adjusted EBITDA margins to 19.9%. Recent acquisition of Passport enhances logistics capabilities, while a $500 million share repurchase program signals management confidence. Technical indicators show the stock trading near resistance at $38 with RSI levels suggesting potential overbought conditions.

GLBE presents a compelling growth story with accelerating international expansion and strong merchant adoption. However, elevated valuation multiples (P/E of 55.69) and recent insider selling warrant caution. The stock's proximity to analyst price targets suggests limited near-term upside, while execution risks around the Passport integration represent key challenges for investors.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE